Mark Collins
About Mark Collins
Mark A. Collins, PhD, age 63, is an independent director of RENB elected at the October 31, 2025 annual meeting; he brings a 40-year career at the intersection of biology, AI, and software with roles spanning biotech startups, large pharma, and tech companies, and holds a PhD in Microbiology (University of Surrey) and a BSc in Applied Sciences (University of Wolverhampton) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Icometrix | VP Translational Services | Prior to 2022 | Led strategy to drive adoption of AI-assisted MRI and digital health tools to improve translational success of CNS therapies |
| Helomics Corp. | Chief Technology Officer | 2017–2021 | Drove technical development and commercialization of AI-driven predictive models for tumor drug response and clinical outcomes |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| UndauntedBio Inc. | Chief Scientific Officer | 2022–Present | AI-driven, clinically informed network-medicine approach to repurposing existing drugs for neuropathic pain |
| Purplebio Consulting, LLC | Founder & Principal Consultant | Ongoing | Scientific, market, and product strategy consulting and execution in life sciences |
Board Governance
- Independence: The Board determined Dr. Collins has no relationships interfering with independent judgment under Nasdaq Listing Rules and is “independent” .
- Election/Shareholder Support: Elected 10/31/2025 with 7,368,381 votes for and 373,601 withheld (1,314,903 broker non-votes overall) .
- Board activity: In FY ended June 30, 2025, the Board held 15 meetings; each director attended at least 75% of Board and committee meetings on which they served .
- Committees and chairs (current charters posted): Audit Committee (McNulty—Chair; members: McNulty, Calder, Collins), Compensation Committee (members: McNulty and Calder), Nominating & Corporate Governance Committee (Calder—Chair; members: McNulty, Collins, Calder) .
- Committee engagement:
- Audit: Met 4 times in FY2025; all meetings attended by each member during their service; Board designated McNulty as “audit committee financial expert” .
- Compensation: Met 2 times in FY2025; acted by written consent 0 times .
- Nominating & Governance: Acted 1 time by written consent in FY2025 .
- Governance policies: Corporate Code of Ethics; Clawback Policy for incentive compensation tied to restatements; Insider Trading Policy including anti-hedging and anti-pledging .
Fixed Compensation
Director compensation policy for independent directors and committee service (as of proxy date):
| Compensation Element | Value ($) |
|---|---|
| Retainer – Board Chair | 100,000 |
| Retainer – Board Members | 60,000 |
| Audit Committee Chair Fee | 15,000 |
| Compensation Committee Chair Fee | 10,000 |
| Nominating Committee Chair Fee | 10,000 |
| Audit Committee Member Fee | 7,500 |
| Compensation Committee Member Fee | 5,000 |
| Nominating Committee Member Fee | 4,000 |
FY2025 actual director compensation (non-employee):
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | All Other ($) | Total ($) |
|---|---|---|---|---|---|
| Mark A. Collins | 52,247 | — | 63,508 | — | 127,247 |
Notes: Option award fair values are computed under ASC 718 and amortized over vesting; amounts shown are accounting fair values, not realized value .
Performance Compensation
Director equity compensation framework and Collins’s FY2025 equity grant:
| Equity Grant Type | Grant Value/Fair Value ($) | Strike Price | Vesting | Expiration | Performance Metrics |
|---|---|---|---|---|---|
| Annual non-employee director stock options (policy) | 75,000 (valuation basis) | Not disclosed | Not disclosed | Not disclosed | None disclosed for director awards |
| Mark A. Collins FY2025 option award (ASC 718 FV) | 63,508 | Not disclosed | Not disclosed | Not disclosed | None disclosed for director awards |
Performance metric detail (directors):
- No performance-conditioned metrics (e.g., revenue growth, EBITDA, TSR) are disclosed for non-employee director equity grants; the 2023 Plan permits performance awards generally, but the director program specifies annual options valued at $75,000 without stated performance conditions .
Other Directorships & Interlocks
| Company | Role | Committee/Position | Notes |
|---|---|---|---|
| None disclosed | — | — | The proxy biography lists operating roles but no other public company directorships for Dr. Collins . |
Expertise & Qualifications
- 40-year career leveraging computers in drug discovery with leadership across biotech, pharma, and tech; led several ventures to successful exits .
- Deep AI/ML and translational science experience: AI-assisted MRI and digital health tools (Icometrix); AI predictive oncology models (Helomics) .
- Educational credentials: PhD in Microbiology (University of Surrey); BSc in Applied Sciences (University of Wolverhampton) .
- Financial literacy: Board states Audit Committee members (including Dr. Collins) possess requisite financial sophistication under Nasdaq standards (McNulty designated audit committee financial expert) .
Equity Ownership
| Holder | Shares Beneficially Owned | % Ownership | Notes |
|---|---|---|---|
| Mark A. Collins, PhD | 12,096 | <1% | Beneficial ownership per SEC rules includes shares with voting/investment power or acquirable within 60 days; company reports 23,178,153 shares outstanding (as of Oct 3, 2025) . |
Policy context:
- Insider Trading Policy includes anti-hedging and anti-pledging; no pledging or hedging of company stock is permitted under the policy framework .
Governance Assessment
- Strengths: Independent status under Nasdaq rules; active committee participation across Audit and Nominating & Governance; Board-level and committee attendance thresholds met in FY2025; adoption of clawback and anti-hedging/anti-pledging policies supports investor-aligned governance .
- Shareholder support: Strong election vote at Oct 31, 2025 annual meeting; say‑on‑pay passed (For: 5,548,091; Against: 2,182,131; Abstain: 11,760; Broker non‑vote: 1,314,903), signaling overall confidence in compensation governance, indirectly bolstering board oversight credibility .
- Watch items: Director equity program relies on time-based options without disclosed performance conditions for directors; Board does not currently have director term limits, and the Chair role is vacant, which may impact leadership continuity if prolonged .
- Conflicts/related‑party exposure: No family relationships among directors and executive officers; no related-person transactions involving Dr. Collins disclosed in the reporting period .
────────
References: